Albany, NY -- (SBWIRE) -- 01/31/2014 -- Orthobiology is a branch of science that develops bone and tissue replacement materials for skeletal and tissue healing. Orthobiologics has been gaining popularity since it provides accelerated healing, faster recovery and reduction in number of hospital visits. A rise in the incidence of arthritis and geriatric population has triggered the growth of this market. Moreover, increase in obesity rate coupled with rise in demand for minimally invasive procedures has created a considerable demand for bone graft substitutes. In addition, technological advancements, growing patient awareness, rising incidences of road accidents and rising participation in sports related activities has considerably augmented the growth of this market.
View Full Report With Complete TOC at http://www.researchmoz.us/orthobiologics-market-allografts-viscosupplements-dbm-bmp-stem-cell-and-others-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019-report.html
The research report on orthobiologics provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of orthobiologics on the basis of different orthobiologic products and applications. The product segment comprises allografts, demineralized bone matrix (DBM), bone morphogenetic proteins (BMPs), viscosupplementation, synthetic bone graft substitutes, stem cell based products and machined bone. The application segment is classified into spinal fusion, trauma and reconstructive surgeries. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments, in terms of USD million, using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations.
The market has also been segmented geographically into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW), and the respective market sizes and forecasts have been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global orthobiologics market, and future opportunities has been provided in the market overview section. This section also features a detailed market attractiveness analysis and Porter’s five force analysis for the orthobiologics market.
The market players are profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include Medtronic, Inc., Stryker Corporation., DePuySythes, Wright Medical Technology, Inc., NuVasive, Inc., Orthofix, Inc., and others.
Browse other Published Reports BY Transparency Market Research at http://www.researchmoz.us/publisher/transparency-market-research-14.html
The global orthobiologicsmarket is segmented into the following categories:
OrthobiologicsMarket, by Products
Demineralized Bone Matrix (DBM)
Bone Morphogenetic Proteins (BMPs)
Stem Cell Therapy
Synthetic Bone Substitutes
OrthobiologicsMarket, by Applications
Orthobiologics Market, by Geography
Related Reports -
Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts. In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.
View Full Report With Complete TOC at http://www.researchmoz.us/gastrointestinal-therapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-to-counter-declines-from-patent-expiries-report.html
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019.
View Full Report With Complete TOC at http://www.researchmoz.us/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth-report.html
Parkinsons Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management
Parkinson’s Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management”. The Parkinson’s Disease (PD) market is dominated by symptomatic treatments targeting functional impairment in PD. Levodopa has remained the gold standard treatment for almost 40 years and has significantly improved patient quality of life. There is currently there is a huge unmet need for disease-modifying treatments that slow progression or have neuroprotective properties. Over the 2012–2019 forecast period, the PD market is anticipated to decline from $3.4 billion in 2012 to $2.9 billion in 2019, as a consequence of upcoming patent expirations of high-profile products such as Azilect, Stalevo and Comtan.
View Full Report With Complete TOC at http://www.researchmoz.us/parkinsons-disease-therapeutics-market-to-2019-pipeline-shows-shift-towards-long-term-disease-management-report.html
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Browse Blog - http://pramoddige91.wordpress.com/